US4997652A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Biodegradable ocular implants
Assignee: Allergan Inc
•
Filing: 1989-05-31
•
Granted: 1991-03-05
•
Expires: 2009-05-31
Abstract
Abstract Encapsulated drugs are employed for introduction into the chambers of the eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.
Inventors
- 👤 Vernon G. Wong
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:32
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/10; A61K9/127; A61K9/0012; A61K9/0048; A61K9/0051; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1641; A61K9/1647
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
55 words
A method for treating an eye condition which comprises: introducing into at least one of the anterior or posterior chamber of an eye at least one microencapsulated drug as particles of not greater than about 2mm, said particles comprising said drug and a pharmacologically acceptable biodegradable polymer or liposome which is degraded in the eye.
Claim 2
Independent Claim
55 words
A method for treating an eye condition which comprises: introducing into at least one of the anterior or posterior chamber of an eye at least one microencapsulated drug as particles of not greater than about 2mm, said particles comprising said drug and a pharmacologically acceptable biodegradable polymer or liposome which is degraded in the eye.
Claim 3
Dependent Claim
12 words
A method according to claim 1, wherein said particle is a liposome.
Claim 4
Dependent Claim
21 words
A method according to claim 1, wherein said particle comprises a biodegradable polymer and is of not greater than about 1mm.
Claim 5
Dependent Claim
13 words
A method according to claim 3, wherein said polymer is a condensation polymer.
Claim 6
Dependent Claim
12 words
A method according to claim 4, wherein said polymer is a polyester.
Claim 7
Dependent Claim
15 words
A method according to claim 5, wherein said polyester comprises an hydroxyaliphatic carboxylic acid monomer.
Claim 8
Dependent Claim
14 words
A method according to claim 6, wherein said hydroxyaliphatic carboxylic acid is lactic acid.
Claim 9
Dependent Claim
15 words
A method according to claim 3, wherein said particle comprises a pharmacologically acceptable buffering agent.
Claim 10
Dependent Claim
13 words
A method according to claim 3, wherein said drug is a growth factor.
Claim 11
Dependent Claim
12 words
A method according to claim 3, wherein said drug is a steroid.
Claim 12
Dependent Claim
16 words
A method according to claim 10, wherein said steroid is hydrocortisone or a pharmacologically acceptable ester.
Claim 13
Dependent Claim
13 words
A method according to claim 3, wherein said drug is a cytotoxic agent.
Claim 14
Dependent Claim
12 words
A method according to claim 12, wherein said cytotoxic agent is methotrexate.
Claim 15
Dependent Claim
25 words
A method according to claim 3, wherein an effective dosage for treatment of said condition is maintained in said chamber for at least one month.
Claim 16
Independent Claim
42 words
A method for treating an eye condition which comprises: introducing into an anterior chamber of an eye a composition of matter comprising liposomes enclosing in their lumen an isotonic solution comprising a pharmacologically active agent which is slowly released in the eye.
Claim 17
Independent Claim
42 words
A method for treating an eye condition which comprises: introducing into an anterior chamber of an eye a composition of matter comprising liposomes enclosing in their lumen an isotonic solution comprising a pharmacologically active agent which is slowly released in the eye.
Claim 18
Dependent Claim
22 words
A method according to claim 15, wherein said liposome has from about 10 to 50 mole percent cholesterol in the lipid bilayer.
Claim 19
Dependent Claim
12 words
A method according to claim 15, wherein said active agent is doxorubicin.
References Cited (Backward Citations)
US3870791A
Cited
US3962414A
Cited
US3914402A
Cited
US4001388A
Cited
US4052505A
Cited
US4057619A
Cited
US4186184A
Cited
US4190642A
Cited
US4303637A
Cited
US4281654A
Cited
US4304765A
Cited
EP0170540A1
Cited
US4853224A
Cited
EP0339861A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-03-04 | 1994-09-03 | 1995-03-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-03-04 | 1998-09-03 | 1999-03-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-03-04 | 2002-09-03 | 2003-03-05 | $7700.00 | Window Closed / Lapsed |